QS21

Phase 2Biologic

MMemorial Sloan Kettering Cancer Center

QS21 is one of 232 biologic programs targeting Metastatic Melanoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

231

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic MelanomaActive, not recruiting

Chronic Myelogenous LeukemiaActive, not recruiting

Breast CancerActive, not recruiting

Colorectal CancerActive, not recruiting

MelanomaActive, not recruiting

Prostate CancerActive, not recruiting

Small Cell Lung CancerActive, not recruiting

KidneyRecruiting

Metastatic MelanomaPhase 1

Active, not recruiting

Chronic Myelogenous LeukemiaPhase 2

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Colorectal CancerPhase 1

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Prostate CancerPhase 1

Active, not recruiting

Small Cell Lung CancerPhase 2

Active, not recruiting

KidneyPhase 1

Recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

QS21

MMemorial Sloan Kettering Cancer Center

Phase 2

3 2

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 3

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 4

Spravato

WWim Janssens

Preclinical

2 5

Chirocaine

PPurdue Pharma LP

Preclinical

1 6

Acupan

YYonsei University

Preclinical

1 7

Chantix

PPrism Pharmaceuticals

Preclinical

1 8

Avastin

Roche

Preclinical

4 9

Nubain

AAultman Health Foundation

Preclinical

1 10

Feraheme

AAzurity Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Kidney

NCT06741072

Clinical

Trials by Indication[1]

Prostate Cancer4 trials

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003819·21 enrolled

Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00579423·30 enrolled

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00004929·15 enrolled

Show 1 more trial

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00036933·9 enrolled

Breast Cancer3 trials

Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence

Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT00030823·14 enrolled

Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer

Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT00470574·7 enrolled

Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003357·9 enrolled

Completed·UUniversity of Virginia·Phase 1·NCT00003224·22 enrolled

4 more indications

Peritoneal Cancer1 trial

Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00006041

Chronic Myelogenous Leukemia1 trial

Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00004052·24 enrolled

Colorectal Cancer1 trial

Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or Colorectal Cancer

Completed·FFox Chase Cancer Center·Phase 1·NCT00006387·7 enrolled

Kidney1 trial

A Phase 1B Double Blinded Randomized Trial Evaluating Safety, Tolerability, and Immune Response of OSU-2131 a BZLF1 Peptide Vaccine With Stimulon™ QS-21 Solution Adjuvant in Healthy Volunteers and Patients Awaiting Solid Organ Transplantation

Recruiting·OOhio State University Comprehensive Cancer Center·Phase 1·NCT06741072·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for QS21. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — QS21 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for QS21. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: MMemorial Sloan Kettering Cancer Center

QS21

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Prostate Cancer4 trials

Breast Cancer3 trials

Melanoma2 trials

Small Cell Lung Cancer1 trial

Metastatic Melanoma1 trial

Peritoneal Cancer1 trial

Chronic Myelogenous Leukemia1 trial

Colorectal Cancer1 trial

Kidney1 trial

References

Drug Info

Quick Facts

Related News